{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:17:56Z","timestamp":1791886676394,"version":"4.3.4"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,2,14]],"date-time":"2015-02-14T00:00:00Z","timestamp":1423872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>\n                    Psychotropic dose equivalence is an important concept when estimating the approximate psychotropic doses patients receive, and deciding on the approximate titration dose when switching from one psychotropic agent to another. It is also useful from a research viewpoint when defining and extracting specific subgroups of subjects. Unification of various agents into a single standard agent facilitates easier analytical comparisons. On the basis of differences in psychopharmacological prescription features, those of available psychotropic agents and their approved doses, and racial differences between\n                    <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                    apan and other countries, psychotropic dose equivalency tables designed specifically for Japanese patients have been widely used in\n                    <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                    apan since 1998. Here we introduce dose equivalency tables for: (i) antipsychotics; (ii) antiparkinsonian agents; (iii) antidepressants; and (iv) anxiolytics, sedatives and hypnotics available in\n                    <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                    apan. Equivalent doses for the therapeutic effects of individual psychotropic compounds were determined principally on the basis of randomized controlled trials conducted in\n                    <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                    apan and consensus among dose equivalency tables reported previously by psychopharmacological experts. As these tables are intended to merely suggest approximate standard values, physicians should use them with discretion. Updated information of psychotropic dose equivalence in Japan is available at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.jsprs.org\/en\/equivalence.tables\/\">http:\/\/www.jsprs.org\/en\/equivalence.tables\/<\/jats:ext-link>\n                    . [Correction added on 8 July 2015, after first online publication: A link to the updated information has been added.]\n                  <\/jats:p>","DOI":"10.1111\/pcn.12275","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T21:25:21Z","timestamp":1421702721000},"page":"440-447","source":"Crossref","is-referenced-by-count":455,"title":["Psychotropic dose equivalence in\n                    <scp>J<\/scp>\n                    apan"],"prefix":"10.1111","volume":"69","author":[{"given":"Toshiya","family":"Inada","sequence":"first","affiliation":[{"name":"Seiwa Hospital Institute of Neuropsychiatry  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Inagaki","sequence":"additional","affiliation":[{"name":"School of International Politics, Economics and Communication Health Administration Center Aoyama Gakuin University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,14]]},"reference":[{"key":"e_1_2_4_2_1","volume-title":"Dose Equivalence of Psychotropic Drugs","author":"Inagaki A","year":"1999"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.144.11.1494"},{"key":"e_1_2_4_4_1","first-page":"69","article-title":"Frequency distribution of CYP2C19, CYP2D6, and CYP2C19 mutant\u2010alleles in several different populations","volume":"16","author":"Kubota T","year":"2001","journal-title":"Yakubutsu dotai (Xenobio Metabol and Dispos)"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-2-6"},{"key":"e_1_2_4_6_1","first-page":"101","article-title":"Dose equivalence of psychotropic drugs. [1] Dose equivalence of orally administered neuroleptics (1)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_7_1","first-page":"215","article-title":"Dose equivalence of psychotropic drugs. [2] Dose equivalence of orally administered neuroleptics (2)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_8_1","first-page":"335","article-title":"Dose equivalence of psychotropic drugs. [3] Dose equivalence of orally administered neuroleptics (3)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_9_1","first-page":"443","article-title":"Dose equivalence of psychotropic drugs. [4] Dose equivalence of orally administered neuroleptics (4)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_10_1","first-page":"681","article-title":"Dose equivalence of psychotropic drugs. [14] Dose equivalence of novel antipsychotics (1): Quetiapine","volume":"4","author":"Inagaki A","year":"2001","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_11_1","first-page":"869","article-title":"Dose equivalence of psychotropic drugs. [15] Dose equivalence of novel antipsychotics (2): Perospirone","volume":"4","author":"Inagaki A","year":"2001","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_12_1","first-page":"997","article-title":"Dose equivalence of psychotropic drugs. [16] Dose equivalence of novel antipsychotics (3): Olanzapine","volume":"4","author":"Inagaki A","year":"2001","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_13_1","first-page":"249","article-title":"Dose equivalence of psychotropic drugs. [17] Dose equivalence of novel antipsychotics (4): Aripiprazole","volume":"9","author":"Inagaki A","year":"2006","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_14_1","first-page":"1443","article-title":"Dose equivalence of psychotropic drugs. [18] Dose equivalence of psychotropic drugs: 2006 version","volume":"9","author":"Inagaki A","year":"2006","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_15_1","first-page":"887","article-title":"Dose equivalence of psychotropic drugs. [21] Dose equivalence of novel antipsychotics (5): Blonanserin","volume":"11","author":"Inagaki A","year":"2008","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_16_1","first-page":"397","article-title":"Dose equivalence of psychotropic drugs. [23] Dose equivalence of novel antipsychotics: Paliperidone extended release","volume":"15","author":"Inagaki A","year":"2012","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(74)90071-5"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033302"},{"key":"e_1_2_4_19_1","volume-title":"New Oxford Textbook of Psychiatry","author":"Gelder MG","year":"2000"},{"key":"e_1_2_4_20_1","first-page":"260","volume-title":"Current Diagnosis & Treatment in Psychiatry","author":"Meltzer HY","year":"2000"},{"key":"e_1_2_4_21_1","volume-title":"Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment","author":"Sadock BJ","year":"2001"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1932"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.2004.01340.x"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0607"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a007071"},{"key":"e_1_2_4_26_1","first-page":"783","volume-title":"Essentials of Clinical Psychiatry","author":"Marangell LB","year":"2004"},{"key":"e_1_2_4_27_1","first-page":"1385","article-title":"Dose equivalency and adequate dose of atypical antipsychotic, quetiapine","volume":"7","author":"Kamijima K","year":"2004","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_28_1","first-page":"1199","article-title":"Dosing strategy for Quetiapine: Its determination and adjustment in schizophrenia","volume":"8","author":"Akimoto T","year":"2005","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_29_1","first-page":"2373","article-title":"Dose equivalence of psychotropic drugs. [20] Dose equivalence of injectable antipsychotics","volume":"10","author":"Inagaki A","year":"2007","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_30_1","first-page":"557","article-title":"Dose equivalence of psychotropic drugs. [5] Dose equivalence of depot neuroleptics (1)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_31_1","first-page":"663","article-title":"Dose equivalence of psychotropic drugs. [6] Dose equivalence of depot neuroleptics (2)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_32_1","first-page":"1349","article-title":"Dose equivalence of psychotropic drugs. [22] Dose equivalence of depot antipsychotics: Risperidone long\u2010acing injection","volume":"13","author":"Inagaki A","year":"2010","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_33_1","first-page":"887","article-title":"Dose equivalence of psychotropic drugs. [8] Dose equivalence of antiparkinsonian drugs (1)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_34_1","first-page":"969","article-title":"Dose equivalence of psychotropic drugs. [9] Dose equivalence of antiparkinsonian drugs (2)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674379403900203"},{"key":"e_1_2_4_36_1","first-page":"606","article-title":"A pilot effort to determine benztropine equivalents of anticholinergic medications","volume":"45","author":"Leon J","year":"1994","journal-title":"Hosp. Community Psychiatry"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1972.01750220084016"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v58n0505"},{"key":"e_1_2_4_39_1","first-page":"1087","article-title":"Dose equivalence of psychotropic drugs. [10] Dose equivalence of antidepressants (1)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_40_1","first-page":"1209","article-title":"Dose equivalence of psychotropic drugs. [11] Dose equivalence of antidepressants (2)","volume":"1","author":"Inagaki A","year":"1998","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_41_1","first-page":"1859","article-title":"Dose equivalence of psychotropic drugs. [19] Dose equivalence of novel antidepressants (1): Sertraline","volume":"9","author":"Inagaki A","year":"2006","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.22.1.15"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70283-5"},{"key":"e_1_2_4_44_1","first-page":"297","article-title":"Dose equivalence of psychotropic drugs. [12] Dose equivalence of anxiolytic drugs, sedatives and hypnotics (1)","volume":"2","author":"Inagaki A","year":"1999","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_45_1","first-page":"411","article-title":"Dose equivalence of psychotropic drugs. [13] Dose equivalence of anxiolytic drugs, sedatives and hypnotics (2)","volume":"2","author":"Inagaki A","year":"1999","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_46_1","first-page":"1403","article-title":"Dose equivalence of psychotropic drugs. [24] Dose equivalence of anti\u2010anxiolytics\/hypnotics (3): Eszopiclone","volume":"15","author":"Inagaki A","year":"2012","journal-title":"Rinsyo Seishin Yakuri (Jpn. J. Clin. Psychopharmacol.)"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.510"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpcn.12275","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.12275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T03:38:11Z","timestamp":1695526691000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.12275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,14]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/pcn.12275"],"URL":"https:\/\/doi.org\/10.1111\/pcn.12275","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,14]]}}}